Germo Gericke, M.D., Chief Medical Officer, first joined Advanced Accelerator Applications (AAA), a Novartis company in 2018, as Head of Research and Development. Prior to joining AAA, Germo served as Franchise Global Program Head in the Oncology Global Development Unit of Novartis, where he led cross-functional development activities for compounds in full development and life cycle management. Prior to moving to Oncology Global Drug Development in 2008, Germo served in strategic, commercial and general management roles with increasing responsibility across a range of therapeutic and geographic areas. Germo joined Novartis in 2001 from McKinsey & Company where he was a member of the Global Healthcare Practice. Germo holds a Medical Doctorate from the University of Heidelberg. He studied medicine at Charité University Hospital, Berlin.